Meeting
2020 ASCO Virtual Scientific Program
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2+/HR+ metastatic breast cancer.
Authors
Matthew Loft
The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
Matthew Loft , Sheau Wen Lok , Richard H. De Boer , Laeeq Malik , Sally Greenberg , Belinda Yeo , Angelyn Anton , Louise M. Nott , Gary Edward Richardson , Ian M. Collins , Javier Torres , Frances Sarah Barnett , Bianca Alix Devitt , Peter Gibbs , Lucy Gately
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1038)
DOI
10.1200/JCO.2020.38.15_suppl.1038
Abstract #
1038
Poster Bd #
123
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Racial disparities in utilization of first line targeted therapies for metastatic breast cancer.
First Author: Yehoda M. Martei
Poster
2022 ASCO Annual Meeting
Post-recurrence survival in asymptomatic compared with symptomatic metastatic breast cancer: A multicenter retrospective study.
First Author: Sayaka Kuba
Poster
2019 ASCO Annual Meeting
Germline BRCA1and BRCA2 mutations in patients with HER2-negative metastatic breast cancer (mBC) treated with first-line chemotherapy: Data from the German PRAEGNANT registry.
First Author: Peter A. Fasching
Poster
2017 ASCO Annual Meeting
A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer (MBC) as first-line chemotherapy (KCSG BR13-11, NCT02263495).
First Author: Kyung Hae Jung